Is Wegovy funded by Pharmac in New Zealand?
⚕ Medically reviewed: pending (before launch)The short answer
No. Pharmac does not fund Wegovy (semaglutide), Mounjaro (tirzepatide) or Saxenda (liraglutide) for weight management. If you and a prescriber decide one of these medicines is right for you, you pay for it privately.
What Pharmac does and doesn't fund
Pharmac is the government agency that decides which medicines are publicly funded in New Zealand. It funds certain GLP-1 medicines for type 2 diabetes under specific Special Authority criteria — but it does not currently fund any medicine for the treatment of weight. That distinction matters: the same active ingredient can be funded for one condition and not another.
So while these medicines are Medsafe-approved (legally available with a prescription), being approved is not the same as being funded. Approval means a doctor can prescribe it; funding means the government subsidises the cost. For weight management, the funding isn't there.
Why isn't it funded?
Pharmac works to a fixed budget and weighs each funding decision against everything else it could fund. Weight-management medicines are newer, in high global demand, and would be a large population cost — so for now they sit outside what's publicly funded here. Pharmac keeps its decisions under review, but there's no funded weight-loss pathway today.
What this means for you
- You'll pay privately for both the medicine and any clinical programme around it.
- It's the same private-cost reality whether you go through a GP, a private prescriber, or a telehealth clinic.
- Cost depends on the medicine, your dose (which usually increases over the first months), and the provider. See our guide on what Wegovy costs in New Zealand.
See if treatment is right for you
A free 3-minute check, then an NZ-registered prescriber confirms suitability. No payment to start.
Check your eligibility →